Mr. Brady Cobb of Splash Beverage reports

SPLASH BEVERAGE GROUP INVESTS IN AVICANNA, A LEADING CANNABINOID BIOPHARMACEUTICAL PLATFORM, ADVANCING ITS TRANSFORMATION INTO CANNABINOID HEALTHCARE

Splash Beverage Group Inc. has completed a $300,000 strategic investment in Avicanna Inc., a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care and developing pharmaceutical products.

The investment represents a strategic capital allocation aligned with Splash's previously announced transformation into a cannabinoid-based health, wellness and health-care-focused platform company.

Splash believes Avicanna has assembled one of the most sophisticated cannabinoid health care platforms operating today and is uniquely positioned for the continued evolution of the medical cannabinoid market in the United States.

"Avicanna has spent years building many of the capabilities we believe will define the future of cannabinoid medicine," said Brady Cobb, interim chief executive officer of Splash Beverage Group. "As we evaluated opportunities across the sector, Avicanna stood out because of its combination of intellectual property, product portfolio, clinical development, health care system integration, managing health insurance filings and integration, pharmaceutical expertise, and operational execution."

Splash's investment thesis is supported by several attributes that management believes distinguish Avicanna within the cannabinoid sector:

• One of North America's leading cannabinoid-based biopharmaceutical companies with proprietary formulations and clinical-stage pharmaceutical assets;
• A commercial-stage pharmaceutical portfolio that includes Trunerox, an approved cannabidiol treatment for severe epilepsy indications, and multiple clinical development programs targeting pain, inflammation and dermatological conditions;
• MyMedi.ca, one of Canada's leading medical cannabis care platforms, providing pharmacist-led patient care, reimbursement support, insurance adjudication and physician-guided patient access;
• Real-world operating experience within Canada's federally regulated medical cannabis system, one of the most advanced medical cannabinoid frameworks globally;
• A vertically integrated international platform that includes pharmaceutical-grade cannabinoid manufacturing and active pharmaceutical ingredient production through its Colombian operations;
• An experienced management team with deep expertise across health care, pharmaceuticals, clinical research and cannabinoid medicine;
• A debt-free balance sheet.

Splash believes the long-term cannabinoid opportunity will increasingly be defined by clinical evidence, physician participation, health care integration, reimbursement infrastructure, pharmaceutical-approved products and regulatory compliance.

Management believes Avicanna has already built a platform around those principles and may be particularly well positioned as the U.S. health care and regulatory environment continues to evolve.

"In many respects, Avicanna has built and operated within a federally regulated medical cannabinoid framework that already incorporates many of the characteristics increasingly being evaluated across the United States health care system," continued Mr. Cobb. "We view this investment as a strategic allocation into a company whose platform, capabilities and operating experience may be uniquely suited for the next phase of cannabinoid medicine."

On June 9, 2026, Splash completed a $300,000 investment in Avicanna's non-brokered private placement, acquiring two million common shares and one million warrants.

About Splash Beverage Group Inc.

Splash Beverage is a publicly traded company headquartered in Fort Lauderdale, Fla. The company is pursuing a strategic transformation toward becoming a cannabinoid health, wellness and biopharmaceutical platform through disciplined capital allocation, strategic investments, acquisitions and other platform-building initiatives.

We seek Safe Harbor.